Multifocal M. intracellulare osteomyelitis in an immunocompetent child.
We report the successful treatment of disseminated Mycobacterium intracellulare osteomyelitis, without evidence of other visceral involvement, in a previously healthy, HIV-negative, 2-year-old female using a 23-month regimen of antimicrobial agents that included 18 months of oral therapy with azithromycin, rifabutin, trimethoprim-sulfamethoxazole (TMP/SMX), and ethambutol.
Raszka
W V
WV
Department of Pediatrics, William Beaumont Army Medical Center, El Paso, Texas 79920.
Trinh
T T
TT
Zawadsky
P M
PM
D017963:Azithromycin / Q000008:administration & dosage / Q000627:therapeutic use; D002675:Child, Preschool; D004359:Drug Therapy, Combination / Q000008:administration & dosage / Q000627:therapeutic use*; D004977:Ethambutol / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D018023:HIV Seronegativity; D006801:Humans; D007121:Immunocompetence; D015269:Mycobacterium avium Complex; D015270:Mycobacterium avium-intracellulare Infection / Q000188:drug therapy*; D010014:Osteolysis / Q000188:drug therapy / Q000382:microbiology; D010019:Osteomyelitis / Q000188:drug therapy* / Q000382:microbiology*; D017828:Rifabutin / Q000008:administration & dosage / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000008:administration & dosage / Q000627:therapeutic use
D017828:Rifabutin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D017963:Azithromycin; D004977:Ethambutol